Karyopharm Therapeutics (KPTI) – Analysts’ Weekly Ratings Changes

A number of firms have modified their ratings and price targets on shares of Karyopharm Therapeutics (NASDAQ: KPTI) recently:

  • 12/12/2017 – Karyopharm Therapeutics was given a new $18.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 12/12/2017 – Karyopharm Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $23.00 price target on the stock.
  • 12/7/2017 – Karyopharm Therapeutics was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 12/6/2017 – Karyopharm Therapeutics was downgraded by analysts at ValuEngine from a “sell” rating to a “strong sell” rating.
  • 11/15/2017 – Karyopharm Therapeutics is now covered by analysts at . They set a “buy” rating and a $23.00 price target on the stock.
  • 11/15/2017 – Karyopharm Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $23.00 price target on the stock.
  • 11/7/2017 – Karyopharm Therapeutics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other major diseases. It serves the healthcare industry throughout the United States. Karyopharm Therapeutics, Inc. is based in United States. “
  • 11/3/2017 – Karyopharm Therapeutics had its “buy” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $15.00 price target on the stock.
  • 11/3/2017 – Karyopharm Therapeutics had its “buy” rating reaffirmed by analysts at Robert W. Baird.

Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) traded up $0.03 during trading on Wednesday, reaching $9.18. The company’s stock had a trading volume of 307,536 shares, compared to its average volume of 234,314. Karyopharm Therapeutics Inc. has a 12-month low of $7.48 and a 12-month high of $14.63.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings data on Thursday, November 2nd. The company reported ($0.65) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.64) by ($0.01). Karyopharm Therapeutics had a negative net margin of 67,267.47% and a negative return on equity of 76.83%. equities research analysts expect that Karyopharm Therapeutics Inc. will post -2.58 EPS for the current fiscal year.

In other news, SVP Christopher Brett Primiano sold 4,958 shares of the firm’s stock in a transaction that occurred on Tuesday, November 7th. The stock was sold at an average price of $11.25, for a total value of $55,777.50. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Sharon Shacham sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 7th. The shares were sold at an average price of $10.39, for a total value of $103,900.00. The disclosure for this sale can be found here. Insiders sold 55,500 shares of company stock valued at $571,269 in the last three months. Insiders own 14.71% of the company’s stock.

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

Receive News & Ratings for Karyopharm Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply